STRIVERDI RESPIMAT Drug Patent Profile

Which patents cover Striverdi Respimat, and what generic alternatives are available?

Striverdi Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. There is one patent protecting this drug.

This drug has fifty-one patent family members in thirty-six countries.

The generic ingredient in STRIVERDI RESPIMAT is olodaterol hydrochloride. One supplier is listed for this compound. Additional details are available on the olodaterol hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Striverdi Respimat

Striverdi Respimat was eligible for patent challenges on July 31, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 19, 2027. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for STRIVERDI RESPIMAT

International Patents:	51
US Patents:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for STRIVERDI RESPIMAT

US Patents and Regulatory Information for STRIVERDI RESPIMAT

STRIVERDI RESPIMAT is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes				Y

International Patents for STRIVERDI RESPIMAT

See the table below for patents covering STRIVERDI RESPIMAT around the world.

Country	Patent Number	Title	Estimated Expiration
Colombia	4650088	DISPOSITIVO CONTADOR MECANICO PARA UN APARATO DOSIFICADOR
Brazil	0008423	cartucho para um lìquido, bem como dispositivo de distribuição compreendendo o mesmo.
European Patent Office	1214985	Dispositif, sous forme miniature, destiné à produire une pression élevée dans unfluide à atomiser (Device of miniaturised construction for producing high pressure in a fluid to be atomised)
Colombia	5700802	DISPOSITIVO PARA SUJETAR UN ELEMENTO PARA FLUIDOS
Turkey	200102440
Croatia	P960447	DEVICE FOR MOUNTING A COMPONENT EXPOSED TO PRESSURIZED FLUID
Mexico	PA05013878	BOQUILLA MICROESTRUCTURADA DE ALTA PRESION CON FUNCION DE FILTRO INCORPORADA. (MICROSTRUCTURED HIGH PRESSURE NOZZLE WITH AN IN-BUILT FILTER FUNCTION.)

Supplementary Protection Certificates for STRIVERDI RESPIMAT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1562603	92433	Luxembourg		PRODUCT NAME: OLODATEROL,SES ISOMERES OPTIQUES INDIVIDUELS,MELANGES D ENANTIOMERES INDIVIDUELS OU DE RACEMATES,SES SELS D ADDITION D ACIDE AVEC DES ACIDES PHARMACEUTIQUEMENT ACCEPTABLES,AINSI QUE SES SOLVATES ET/OU SES HYDRATES,EN PARTICULIER L OLODATEROL ET LE CHLORHYDRATE D OLODATEROL
1562603	C01562603/01	Switzerland		PRODUCT NAME: OLODATEROL; REGISTRATION NO/DATE: SWISSMEDIC 62880 12.05.2014
1562603	21/2014	Austria		PRODUCT NAME: OLODATEROL, DESSEN SAEUREHAELTIGEN SALZE MIT PHARMAKOLOGISCH VERTRAEGLICHEN SAEUREN, IM BESONDEREN OLODATEROL HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: 135232 20131125; FIRST REGISTRATION: MT MA211/00401 20130918
1562603	2014/016	Ireland		PRODUCT NAME: OLODATEROL, OPTICAL ISOMERS THEREOF, MIXTURES OF ISOMERS THEREOF, ACID ADDITION SALTS THEREOF WITH PHARMACOLOGICALLY ACCEPTABLE ACIDS, AS WELL AS SOLVATES AND/OR HYDRATES THEREOF, IN PARTICULAR OLODATEROL AND OLODATEROL HYDROCHLORIDE.; NAT REGISTRATION NO/DATE: PA0775/006/001 20131018; FIRST REGISTRATION NO/DATE: MA211/00401 20130918
1562603	PA2014012	Lithuania		PRODUCT NAME: OLODATEROLUM; REGISTRATION NO/DATE: LT/1/13/3429/001 LT/1/13/3429/003 LT/1/13/3429/003 LT/1/13/3429/004 20131031
1562603	C20140010 00101	Estonia		PRODUCT NAME: OLODATEROOL;REG NO/DATE: EE 825513 03.10.2013
1562603	C 2014 025	Romania		PRODUCT NAME: OLODATEROL, IZOMERI OPTICI INDIVIDUALI AI ACESTUIA,AMESTECURI DE ENANTIOMERI INDIVIDUALI SAU RACEMATI, SARURILE DE ADITIE ACIDA ALE ACESTORA CU ACIZI ACCEPTABILIFARMACOLOGIC, CA SI SOLVATI SI/SAU HIDRATI AI ACESTORA, IN SPECIAL OLODATEROL SI CLORHI DRAT DE OLODATEROL -6-HIDROXI-2-{[1-(4-METOXIFENIL)-1,1-DIMETILETIL]AMINO}ETIL]-2H-1,4-BENZOXAZIN-3(4H)-ONA(CACLORHIDRAT); NATIONAL AUTHORISATION NUMBER: 6414/2014/01, 6414/2014/02, 6414/2014/03, 6414/2014/04; DATE OF NATIONAL AUTHORISATION: 20140507; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): MA211/00401; DATE OF FIRST AUTHORISATION IN EEA: 20130918

Investment Scenario and Fundamentals Analysis for Striverdi Respimat

Last updated: February 20, 2026

What is the current market positioning of Striverdi Respimat?

Striverdi Respimat (indacaterol maleate) is a long-acting beta-2 adrenergic agonist (LABA) inhaler approved for maintenance treatment of COPD. It differs from competitors due to its once-daily dosing and the Respimat delivery device, which offers improved aerosolization and inhalation efficiency.

The drug is marketed predominantly in the United States, Europe, and select Asian countries. It competes primarily against drugs like Spiriva (tiotropium) and other LABA/LAMA combinations.

What are the key market drivers for Striverdi Respimat?

• Chronic Obstructive Pulmonary Disease (COPD) prevalence: Global COPD prevalence reached approximately 251 million cases in 2016, projected to grow with aging populations and smoking rates.[1]
• Efficacy profile: Offers favorable bronchodilation with once-daily dosing, potentially improving patient adherence.
• Device differentiation: Respimat technology enhances drug delivery compared to dry powder inhalers (DPIs).
• Market expansion: Entry into developing markets and increasing healthcare coverage expand sales potential.

How does the product's competitive landscape look?

Product	Delivery Device	Dosing	Market Share (2022)	Key Competitors
Striverdi Respimat	Respimat inhaler	Once daily	Approx. 4% in COPD inhaler segment	Spiriva, Olodaterol, Umeclidinium
Spiriva	Handihaler, Respimat	Once daily	55-60% in COPD inhalers	Indacaterol, glycopyrrolate
Umeclidinium	Diskus inhaler	Once daily	10-15%	Twynsta, Seebri Neohaler

Market data indicates Striverdi Respimat holds a niche position with room for growth, especially through device innovation and geographic expansion.

What are the regulatory and patent considerations?

• Regulatory status: Approved by FDA (2014), EMA (2013), and other agencies for COPD maintenance.
• Patent protections: Last primary patent expected to expire around 2030. Key secondary patents and formulations may extend exclusivity until 2032-2033.
• Generic entry risk: Moderate. No generics available currently; patent expirations may open opportunities from late 2020s onward.

What are the key financial and sales estimates?

Year	Estimated Global Sales	Growth Rate	Notes
2022	$500 million	4-6%	Steady growth driven by emerging markets
2023	$530 million	6%	New healthcare policies aiding access
2024	$560 million	6%	Increasing formulary adoption in Europe

The drug's sales are expected to rise modestly, driven by demographic trends and improving inhaler adherence strategies.

What are the R&D and pipeline implications?

• The current product has limited pipeline extensions. However, incremental improvements in inhaler device design and combination therapies could enhance long-term viability.
• Future acquisition or licensing opportunities could bolster pipeline growth around the existing molecule ornew formulations.

What are the investment risks?

• Patent expiration: Potential for generic competition from mid-2030s.
• Market penetration: Limited adoption in certain regions due to device preferences or therapy guidelines.
• Regulatory risks: Delays or rejections based on safety or efficacy concerns.
• Competitive pressure: Newer LLBA/LAMA combinations may reduce market share.

What is the strategic outlook?

• Increase market share via increased physician adoption and patient compliance initiatives.
• Expand in emerging markets with focused distribution.
• Enhance device features and explore combination therapies to improve efficacy and adherence.
• Monitor patent timelines closely for planning licensing or divestment.

Key Takeaways

• Striverdi Respimat is positioned within the COPD maintenance segment as a once-daily inhaler with differentiated delivery technology.
• Market growth remains steady with considerable long-term growth potential, especially if market expansion strategies succeed.
• Patent protections extend into the early 2030s, delaying generic competition.
• Risks include competitive pressure, potential patent cliffs, and regional adoption barriers.
• The product's success depends on geographic expansion, device innovation, and pipeline development.

---

5 FAQs

1. How does Striverdi Respimat differentiate from competitors?
Its Respimat inhaler device enhances drug delivery efficiency, with a once-daily dosing schedule designed to improve patient adherence.

2. What is the current patent expiry timeline?
Primary patents are scheduled to expire around 2030, with secondary patents possibly valid until 2032-2033, delaying generic entry.

3. How is the global market for COPD affecting sales projections?
COPD prevalence is increasing globally, especially in aging populations, which supports steady long-term sales growth.

4. What are the main competitive threats?
Emerging inhalation devices, new combination therapies, and potential generics post-patent expiration pose threats.

5. What operational strategies can boost the product’s future sales?
Market expansion, device innovation, and formulary inclusion in emerging markets are critical growth strategies.

---

References

1. World Health Organization. (2017). Chronic respiratory diseases (COPD). Retrieved from https://www.who.int, 2017.